29. Bovy C, Gothot A, Delanaye P et al. Impact of haemoglobin and erythropoietin dose changes on mortality: a secondary analysis of results from a randomized anaemia management trial Abstract Background. Anaemia is a common complication of chronic kidney disease. A number of studies have identified an adverse association between haemoglobin (Hgb) variability and mortality. To date, no study has evaluated the impact of Hgb variability on mortality in the setting of a uniform Hgb target and erythropoiesis-stimulating agents (ESA) dosing strategy. Methods. One hundred and fifty-four haemodialysis (HD) patients from a previous randomized anaemia management study were followed up for up to 6 years. 
Introduction
Anaemia is a common complication of chronic kidney disease (CKD) and end-stage renal disease (ESRD). The introduction of erythropoiesis-stimulating agents (ESA) has led to a dramatic reduction in blood transfusion requirements and has been associated with improved quality of life and exercise capacity [1] [2] [3] . However, a number of studies in both ESRD [4] and CKD [5] [6] [7] have evaluated the impact of normalizing haemoglobin (Hgb) beyond traditional targets with ESA and have demonstrated harm. A recent meta-analysis supports this conclusion [8] , although further studies are needed. The reasons why Hgb normalization could be harmful are not clear; a recent post hoc analysis of one of the aforementioned randomized trials suggested that higher ESA doses may play a role [9] . Observational studies suggest that there is a reverse J-shaped relationship between Hgb concentration and outcome in both the general population [10, 11] and in ESRD [12] ; however, the curve is shifted to lower Hgb values in the ESRD group. The nadir of this curve presumably represents the optimum Hgb concentration to maximize oxygen delivery, balancing the opposing effects of oxygen content vs blood viscosity, which appears to be increased in patients with renal disease [13] . ESAs may also have negative cardiovascular effects by promoting arterial stiffness and hypertension, mediated through an increase in blood viscosity and inhibition of nitric oxide synthesis [14] . Additionally, ESAs have been shown to improve platelet function, perhaps increasing the risk of thrombosis [15, 16] . Additionally, a plethora of studies have been published in the last several years pointing to the adverse associations between variability in Hgb levels in patients and important clinical outcomes including mortality [17] [18] [19] [20] [21] [22] [23] . To what extent this variability is intrinsic to patients or related to external factors, including the abrupt non-physiologic increases of circulating ESA levels with ESA therapy, has been reviewed recently [24] . Most of the studies on the relationship between Hgb variability and outcome have been derived from databases and are strengthened by patient numbers but potentially limited by the lack of detail regarding specific anaemia management practices. Hgb targets in individual patients may vary and details about the prescribing practices of ESA in these patients are often lacking in such studies.
We previously published a randomized controlled trial evaluating the usefulness of an anaemia management protocol to achieve Hgb targets [25] . The purpose of the present study was to determine if Hgb variability and various attributes of ESA therapy, including dosing patterns of ESA and use of intravenous (IV) iron supplementation, were associated with subsequent mortality.
Materials and methods

Study population
The study design has been discussed in detail previously [25] . In brief, this was a single-centre, randomized controlled trial in which consenting, prevalent haemodialysis (HD) patients on ESA (Eprex © ; Jansen-Ortho) were allocated to either protocolized anaemia management or to usual care by a primary nephrologist and nurse clinician over an 8-month period. The desired Hgb range was set at 110-125 g/L; nephrologists whose patients were participating in the control arm of the study were asked to aim for this target range. The maximum ESA dose prescribed in the centre was 30 000 units weekly. All patients in the protocol group not on iron supplementation at enrolment were started on oral ferrous gluconate 600-900 mg daily. IV iron sucrose (Venofer © ; Luitpold Pharmaceuticals Inc.) was prescribed if ferritin was <100 µg/L or the transferrin saturation (TSAT) was <20% and the Hgb was below the range. Patients received 100 mg intravenously over each of the next 10 HD treatments and then every 2 weeks thereafter. Iron was held if ferritin was >800 µg/L or the TSAT was >50%. Those patients who had completed at least 20 weeks of the original study and were alive on HD at the end of the study were followed up in the present analysis using data collected during or at the end of the original study as baseline data. Anaemia management of these patients returned to the primary nephrologist and nurse clinician at completion of the original study-no specific anaemia protocol was followed. All study participants were on HD at St. Joseph's Healthcare in Hamilton, ON, Canada. The study was approved by the hospital ethics review board.
Outcomes
The primary outcome was all-cause mortality. Outcome data was retrospectively extracted from hospital and office charts and the hospital information system. Patients were followed up from completion of the original anaemia management study (July 2002) until June 2008. Subjects were censored for transfer or loss to follow-up, renal transplantation or end of the study.
Laboratory parameters
All laboratory parameters used as predictor variables were prospectively collected during the original study. Hgb values were obtained before the midweek dialysis session every 2 weeks. Serum ferritin, TSAT, albumin levels and the urea reduction ratio (URR) were obtained monthly.
Haemoglobin variance
Hgb variability was measured in three ways. In the first method, analogous to a previously described method [19] , the residual deviation between the final six Hgb values from the original study and the mean Hgb target level (117.5 g/L) (rather than individual regression lines) was designated SD Hgb mean and calculated as follows ( Figure 1A Finally, as previously described [19] , the velocity of Hgb change was determined by averaging the absolute slopes between successive Hgb values throughout the original study (see Figure 1C ):
Furthermore, average positive-only (Hgb increases) and negative-only (Hgb decreases) deflections were also calculated: Hgb deflect pos was restricted to those values where ai bi > 0 and Hgb deflect neg was restricted to those values where ai bi < 0.
Anaemia management parameters
In addition to the ability to achieve Hgb target at baseline, the average ESA dose, average and relative ESA dose change and frequency of ESA dose changes and holds were recorded prospectively during the original study and probed as potential predictor variables. ESA dose increases and decreases were also separately averaged during the original study and expressed as discrete variables. IV iron use and average iron dose (in milligrams per week) during the trial were also recorded prospectively.
Statistical analysis
Associations of Hgb variability and ESA dosing parameters with mortality over the 6-year period were estimated using Cox proportional hazards regression modelling adjusted for baseline known mortality predictors. Survival differences between tertiles of average ESA dose change were analysed using the log-rank statistic for Kaplan-Meier survival curves. Univariate estimates of the associations between Hgb variability and clinical and laboratory parameters were determined using linear regression. Independent associations were determined using stepwise multivariable linear regression on significant univariate parameters (P<0.10). The impact of original group assignment on change in Hgb variability parameters over time was analysed by calculating individual slope values from fitted regression equations for each subject. Differences between mean slopes for each group were then analysed using the Student's t-test.
Final P-values <0.05 were considered statistically significant. Data analysis was carried out using the SPSS v. 15.0 (SPSS Inc.) software package.
Results
One hundred and fifty-four of the original 167 patients were alive on HD at completion of the randomized controlled trial. Follow-up was from July 2002 to June 2008 (6 years). Thirty subjects were censored because of renal transplantation (29) or loss to follow-up (1) and there were 91 deaths during the follow-up period. Baseline characteristics (values obtained at completion of the original study) of the cohort are shown in Table 1 . ESA dose was approximately 11 000 units weekly and the average dose change was about 43% of this value. Univariate Cox associations with mortality are shown in Table 2 . Usual predictors of mortality, including serum albumin, age, coronary artery disease (CAD) and diabetes mellitus (DM) were observed in this follow-up period. In addition, ESA dose and magnitude of dose change, IV iron dose and measures of ability to achieve target Hgb (SD Hgb mean and SD Hgb range ) were also associated with mortality. In univariate analysis, Hgb deflect pos had a stronger association with mortality than either the overall absolute deflection or Hgb deflect neg . Other parameters not associated with mortality in univariate analysis were gender, average baseline Hgb, URR, original group assignment and blood pressure. Iron dose was expressed either as a continuous variable or as a dichotomous variable based on a threshold of 38.5 mg/week, corresponding to findings from a previous study [26] . Results of several Cox proportional hazards models for mortality are shown in Figure 2 shows the Kaplan-Meier survival curves for subjects based on tertiles of average ESA dose increase (χ 2 =9.73, P=0.0018). To further explore reasons for the independent association of Eprex dose increase with mortality, the original two arms of the study were compared. Subjects in the control group had a significantly higher Figure 3 shows the change in the parameter Hgb deflect pos over time during the original study. The magnitude of Hgb deflect pos appears to decrease over time in the protocol group but not in the control group, although these differences did not achieve statistical significance (P=0.10). Predictors of the mortality risk factor Hgb deflect pos were explored in multivariate linear regression analysis (Table 4) . 
Discussion
This study confirms previous reports that some, but not all, measures of Hgb variability are independently associated with survival [17] [18] [19] 21] . In addition, larger ESA dose increases were associated with increased mortality, a novel finding.
A number of studies have now shown that measures of Hgb variability are associated with increased mortality when adjusted for other potential confounders [18, 19, 21] , although a study on a more contemporary cohort did not [17] . Various methods to measure Hgb variability have been described and have been recently reviewed [24] . The present study utilized techniques similar to previously described methods [17] [18] [19] with some novel features. Rather than using the individual patient's Hgb trend as a reference to determine Hgb deviation, the present study has the advantage of using actual Hgb target (mean or range). In addition, Hgb deflections over time were broken down into both decreases and increases to ascertain their individual associations with patient outcomes. This study, while much smaller than previous studies, has the advantage of having uniform Hgb targets in patients and, equally important, detailed information regarding their anaemia management parameters, including dose of ESA used and its adjustment over time during the original randomized controlled trial [25] .
Patients with greater deviations of Hgb levels from either the target mean or the limits of the range (110 and 125 g/L) had a greater risk of death in univariate analysis which did not persist when adjusted for other factors, although there was a trend to increased hazard associated with SD Hgb range , a novel Hgb variability parameter. The lack of association of these two Hgb variability metrics with mortality after adjustment for potential confounders differs from most previous studies examining the influence of Hgb variability on patient outcomes [18, 19, 21] . This may simply be a power issue as the present study is smaller than those previously described. Alternatively, these variability metrics may differ suffi- ciently from those used in the aforementioned studies to explain the difference in findings.
Regarding the third measure of Hgb variability, positive, but not negative, Hgb deflections were associated with increased mortality after adjustment for potential confounders. This association persisted after the inclusion of ESA dosing parameters and has not been, to our knowledge, previously described. It is intriguing that more rapid decline in Hgb on average was not associated with mortality in multivariate analysis. This is despite the fact that one would anticipate that more dramatic Hgb drops may relate more to intrinsic factors such as intercurrent illness or inflammation. On the other hand, a more rapid rise in Hgb was associated with increased mortality and may in part relate to ESA-prescribing factors of which healthcare providers have some measure of influence.
The rate of Hgb rise (Hgb deflect pos ) would appear to be modifiable. Graphically, there appeared to be a decrease in the magnitude of Hgb deflect pos in subjects randomized to an anaemia management algorithm that was not observed in the control group. This was likely in part due to the lower average ESA dose increase observed in the protocol group. It is noteworthy that there was a trend to improved survival in the protocol group despite the fact that any potential benefits of the algorithm likely diminished over time once anaemia management was relinquished back to the primary nephrologists. A randomized trial looking at the impact of different ESA dosing strategies in response to patients' Hgb levels and/or trends is needed to further explore whether the magnitude of ESA dose changes has any direct effect on patient outcomes. Artificial neural network modelling of individual Hgb response to ESA therapy may play a role in improving the management of anaemia in ESRD patients [27] .
There has been an appropriate increase in concern with the use of ESAs to target normal Hgb levels in patients with CKD, based on the findings of several trials [4] [5] [6] . A recent post hoc analysis of one of these trials pointed to the possibility that ESA dose was a potential mediator of the increased risk of harm noted in patients randomized to the higher Hgb target [9] . Additionally, ESA requirements have also been shown to predict mortality [28] , whereas ESA 'responsiveness' is associated with decreased mortality [29] . While ESA dose was predictive of mortality in univariate analysis in the present study, the magnitude of ESA dose increase was a stronger predictor of mortality which persisted after adjustment for other variables, whereas average ESA dose was not. For every 1000-unit ESA dose increase, there was an associated 12% increase in mortality which was significant. To our knowledge, this has not been previously described.
The reasons why the magnitude of ESA dose increases was associated with harm are not clear. It is likely that this observation is at least in part related to a tendency for greater changes in ESA dose to be made in patients who are less responsive to ESA or in those who have had intercurrent illnesses leading to a drop in Hgb and the need for higher doses of ESA. However, in a multivariable analysis, adjusting for comorbid conditions such as DM, CAD and a marker of inflammation (albumin), ESA dose increases still predicted death. It is plausible that large increases in ESA dose may have harmful effects, either through sudden increases in Hgb leading to thrombosis [30] or through other pleiotropic effects of erythropoietin including its effects on the vasculature via nitric oxide inhibition [14, 31] , increased oxidative stress [32] and improved platelet function [15, 16, 33] . The observation that positive but not negative Hgb deflections were also independently associated with mortality suggests that the impact of ESA dose increases may be primarily mediated through its effects on red blood cell production. It is tempting to hypothesize that patients with more rapid rises in Hgb related to substantial ESA dose increases or persistently high ESA doses in the setting of resolving ESA resistance are at increased risk for adverse outcomes compared to others. It is, however, difficult to reconcile this with the observation that ESA responsiveness is associated with improved survival [29] . It is worth reiterating that the predictor variables, Hgb deflect pos and ESA dose increase, represent average baseline values acquired during an anaemia management study to predict future outcome and were not time-dependent in nature. Their importance as mortality predictors may reflect individual patients' intrinsic responsiveness to ESA therapy, cautioning against too abrupt an increase in ESA dose.
In light of the findings that positive Hgb deflection was associated with increased mortality and appeared to be modifiable, predictors of this variable were explored. A significant proportion of the variability in Hgb deflect pos could be attributed to factors of which we have some control, including magnitude of ESA dose increase and number of ESA dose changes. It has been previously suggested that usual approaches to anaemia management provoke Hgb oscillations and, therefore, more ESA-responsive patients may need to be treated with smaller dose increments [34, 35] , a suggestion supported by the present findings. Surprisingly, use of a catheter as an HD vascular access was associated with a more rapid Hgb increase. Why the use of a catheter was associated with Hgb deflect pos is unknown-whether this reflects residual confounding is unclear and merits further investigation. Catheter use has been shown to be associated with increased cardiovascular (and infectious) mortality compared to utilization of an arteriovenous fistula [36] [37] [38] [39] , this could be in part related to the association between Hgb change and catheter use observed in the present study.
The present study is not without limitations. Outcomes were collected retrospectively; however, the use of mortality as the outcome is less subject to bias and only one subject was lost to follow-up. Although variables likely to affect outcome were included and estimates derived from a statistically sound model, Hgb variability and ESA dosing could be associated with other underlying patient characteristics not captured in our study that may account for the major factors associated with the outcome of interest. This residual confounding would then lead to biases in the estimates of association described herein. Many of the variables of interest are time-dependent and subsequent changes over time may influence future events or serve as intermediaries between exposure and outcome [18] . In the present study, summary values of the variables of interest from the initial study period were used to describe future risk of death. As patients were no longer in an anaemia management study after the time period in question, future values were not collected and used as timedependent variables. This may lead to exclusion of other potential confounding variables from our dataset. In addition, variables such as Hgb change and ESA dosing changes are intricately linked, limiting inferences on the relative importance of each on outcomes of interest. Nevertheless, the findings in the present study are thought-provoking and hypothesis-generating.
Conclusion
In conclusion, the present study demonstrates that the rate of Hgb rise and magnitude of ESA dose increase were independently associated with mortality in HD patients. Some of the factors influencing these anaemia management variables are modifiable. A large randomized trial of sufficient duration is needed to evaluate the impact of different ESA dosing adjustment strategies on important clinical outcomes in HD patients.
